Plain-English translation of NCT04697810 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a medication called to treat non-alcoholic steatohepatitis (NASH), a serious liver condition where fat builds up in the liver and causes inflammation and scarring. The study will enroll about 114 people and compare the medication to placebo over 36 weeks, with regular check-ins and blood tests to see if the treatment helps improve liver health.
NASH is a growing health problem with no FDA-approved treatments yet. This study aims to determine whether this medication can reduce liver inflammation, prevent scarring from getting worse, and improve how the liver functions in people with this disease.
If you are selected, you'll take capsules of either the new medication or placebo twice a day for 36 weeks. You'll visit the clinic regularly for blood tests and other check-ups, and you'll have two liver biopsies—one at the beginning to confirm your diagnosis and one at the end to see if the treatment worked. After finishing the medication, you'll have one more follow-up visit about 6 weeks later. In total, this commitment lasts about 9–10 months.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Bosnia and Herzegovina
Bulgaria